We'll likely never know that any discussions are taking place until a formal offer is announced to shareholders.
We know the results are incredible. I think it is fair to assume that there would be interest from BP (but that is just my opinion).
I don't think we should undersell the fact that we have 3 FTDs (with one being for a therapy product). I would have thought those recent designations might start to pique interest.
A quick case study...
1. 24 APR 2023 - Point Biopharma gets fast track for its PSMA radioligand therapy. 2. JUN 2023 - Eli Lilly reps and Point reps get chatting at some conferences. They enter into a confidentiality agreement so that due dilligence can be completed etc. 3. OCT 2023 - Eli Lilly buys point for 1.4b USD.
CU6 Price at posting:
$2.83 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)